{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:12:14Z","timestamp":1791396734442,"version":"4.3.3"},"reference-count":38,"publisher":"Royal College of Psychiatrists","issue":"1","license":[{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"unspecified","delay-in-days":129,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur. Psychiatr."],"published-print":{"date-parts":[[2021]]},"abstract":"<jats:title>Abstract<\/jats:title>\n\t  <jats:sec id=\"S0924933821000304_sec1\">\n\t    <jats:title>Background<\/jats:title>\n\t    <jats:p>The aim of this pooled analysis was to evaluate the efficacy and safety of lurasidone in the treatment of an acute exacerbation of schizophrenia in adolescents and young adults.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S0924933821000304_sec2\" sec-type=\"methods\">\n\t    <jats:title>Methods<\/jats:title>\n\t    <jats:p>The six pooled studies in this analysis used similar study designs and outcome measures. Patients (aged 13\u201325 years) were randomized to 6\u00a0weeks of double-blind, placebo-controlled treatment with lurasidone in fixed doses of 40, 80, 120, or 160\u00a0mg. The primary efficacy endpoint was Week\u00a06 change in the Positive and Negative Syndrome Scale (PANSS) total score; secondary efficacy endpoints included Week\u00a06 change in the Clinical Global Impression\u2013Severity scale.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S0924933821000304_sec3\" sec-type=\"results\">\n\t    <jats:title>Results<\/jats:title>\n\t    <jats:p>The safety population consisted of 537 patients (mean age: 18.1\u00a0years); 82.6% of patients completed the studies. Treatment with lurasidone was significantly better than placebo at all doses (<jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.001) for change in the PANSS total score at Week 6. Placebo-adjusted PANSS scores ranged from \u22129.4 to \u221216.1 (effect sizes: 0.53\u20130.90), with effect sizes increasing at higher doses. For lurasidone (combined doses), three adverse events occurred with a frequency of \u22655% (nausea: 13.5%; somnolence: 12.1%; akathisia: 10.1%). At last observation carried forward (LOCF)-endpoint weight gain of \u22657% was similar for lurasidone versus placebo (3.6 vs. 4.7%). Minimal median changes were observed at endpoint in cholesterol, \u22122.0\u00a0mg\/dL; triglycerides, 0.0\u00a0mg\/dL; and glucose, 0.0\u00a0mg\/dL.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S0924933821000304_sec4\" sec-type=\"conclusions\">\n\t    <jats:title>Conclusions<\/jats:title>\n\t    <jats:p>In adolescents and young adults with schizophrenia, treatment with lurasidone in doses of 40\u2013160\u00a0mg\/d was a safe, well-tolerated, and effective treatment. Short-term treatment with lurasidone was associated with minimal effects on weight and metabolic parameters.<\/jats:p>\n\t  <\/jats:sec>","DOI":"10.1192\/j.eurpsy.2021.30","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T08:38:16Z","timestamp":1620635896000},"source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: A pooled post hoc analysis of double-blind, placebo-controlled 6-week studies"],"prefix":"10.1192","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4212-8136","authenticated-orcid":false,"given":"Isabella","family":"Costamagna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2063-6132","authenticated-orcid":false,"given":"Fabrizio","family":"Calisti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Pikalov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2021,5,10]]},"reference":[{"key":"S0924933821000304_r11","doi-asserted-by":"publisher","DOI":"10.1097\/XCE.0000000000000063"},{"key":"S0924933821000304_r4","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2020.03.045"},{"key":"S0924933821000304_r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.01.009"},{"key":"S0924933821000304_r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2018.03.008"},{"key":"S0924933821000304_r36","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20765"},{"key":"S0924933821000304_r10","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30132-4"},{"key":"S0924933821000304_r8","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15m10479"},{"key":"S0924933821000304_r27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI93362"},{"key":"S0924933821000304_r38","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(15)00115-7"},{"key":"S0924933821000304_r1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60486-9"},{"key":"S0924933821000304_r2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-0364-0"},{"key":"S0924933821000304_r22","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852920001893"},{"key":"S0924933821000304_r12","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.167346"},{"key":"S0924933821000304_r7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1549"},{"key":"S0924933821000304_r33","first-page":"217","volume-title":"ECDEU assessment manual for psychopharmacology","author":"Guy","year":"1976"},{"key":"S0924933821000304_r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2013.01.020"},{"key":"S0924933821000304_r37","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0588-3"},{"key":"S0924933821000304_r32","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"S0924933821000304_r6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2014.08.009"},{"key":"S0924933821000304_r28","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-018-0063-7"},{"key":"S0924933821000304_r26","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2009.10.010"},{"key":"S0924933821000304_r13","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04905"},{"key":"S0924933821000304_r34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31135-3"},{"key":"S0924933821000304_r29","volume-title":"Diagnostic and statistical manual of mental disorders","year":"1994"},{"key":"S0924933821000304_r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2010.09.011"},{"key":"S0924933821000304_r30","volume-title":"Diagnostic and statistical manual of mental disorders","year":"2000"},{"key":"S0924933821000304_r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.03.013"},{"key":"S0924933821000304_r20","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115620460"},{"key":"S0924933821000304_r21","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2016.0189"},{"key":"S0924933821000304_r14","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10060907"},{"key":"S0924933821000304_r18","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32835281ef"},{"key":"S0924933821000304_r15","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-012-2838-2"},{"key":"S0924933821000304_r5","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2015.2923"},{"key":"S0924933821000304_r24","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852920000760"},{"key":"S0924933821000304_r31","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2012.11.004"},{"key":"S0924933821000304_r23","doi-asserted-by":"publisher","DOI":"10.1192\/pb.bp.114.048793"},{"key":"S0924933821000304_r25","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300027"},{"key":"S0924933821000304_r3","doi-asserted-by":"publisher","DOI":"10.1111\/eip.12412"}],"container-title":["European Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924933821000304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T08:30:55Z","timestamp":1622795455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924933821000304\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021]]}},"alternative-id":["S0924933821000304"],"URL":"https:\/\/doi.org\/10.1192\/j.eurpsy.2021.30","relation":{},"ISSN":["0924-9338","1778-3585"],"issn-type":[{"value":"0924-9338","type":"print"},{"value":"1778-3585","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"article-number":"e35"}}